| Gastroenteropancreatic neuroendocrine tumors: standardizing therapy monitoring with 68Ga-DOTATOC PET/CT using the example of somatostatin receptor radionuclide therapy. | |
| | |
MedLine Citation:
|
PMID: 21084031 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
The purpose of this study was to standardize therapy monitoring of hepatic metastases from gastroenteropancreatic neuroendocrine tumors (GEP-NETs) during the course of somatostatin receptor radionuclide therapy (SRRT). In 21 consecutive patients with nonresectable hepatic metastases of GEP-NETs, chromogranin A (CgA) and 68Ga-DOTATOC PET/CT were compared before and after the last SRRT. On 68Ga-DOTATOC PET/CT, the maximum standard uptake values (SUVmax) of normal liver and hepatic metastases were calculated. In addition, the volumes of hepatic metastases (volume of interest [VOI]) were measured using four cut-offs to separate normal liver tissue from metastases (SUVmax of the normal liver plus 10% [VOIliver+10%], 20% [VOIliver+20%], 30% [VOIliver+30%] and SUV = 10 [VOI10SUV]). The SUVmax of the normal liver was below 10 (7.2 ± 1.3) in all patients and without significant changes. Overall therapy changes (Δ) per patient (mean [95% CI]) were statistically significant with p < .01 for ΔCgA = -43 (-69 to -17), ΔSUVmax = -22 (-29 to-14), and ΔVOI10SUV = -53 (-68 to -38)% and significant with p < .05 for ΔVOIliver+10% = -29 (-55 to -3)%, ΔVOIliver+20% = -32 (-62 to -2) and ΔVOIliver+30% = -37 (-66 to -8). Correlations were found only between ΔCgA and ΔVOI10SUV (r = .595; p < .01), ΔSUVmax and ΔVOI10SUV (0.629, p < .01), and SUVmax and ΔSUVmax (r = -.446; p < .05). 68Ga-DOTATOC PET/CT allows volumetric therapy monitoring via an SUV-based cut-off separating hepatic metastases from normal liver tissue (10 SUV recommended). |
| | |
Authors:
|
Wolfgang Luboldt; Holger Hartmann; Bärbel Wiedemann; Klaus Zöphel; Hans-Joachim Luboldt |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Molecular imaging : official journal of the Society for Molecular Imaging Volume: 9 ISSN: 1536-0121 ISO Abbreviation: Mol Imaging Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101120118 Medline TA: Mol Imaging Country: United States |
Other Details:
|
Languages: eng Pagination: 351-8 Citation Subset: IM |
Affiliation:
|
Multiorgan Screening Foundation, and Department of Radiology, University Hospital Frankfurt, Theodor-Stern-Kai 7, Frankfurt, Germany. luboldt@screening.org |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid interference in a human ...
Next Document: Excessive medical information increase in package inserts.